e-learning
resources
Glasgow 2004
Sunday 05.09.2004
New and emerging pharmacological strategies in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification
J. Bousquet, G. Ayre, M. Blogg (Montpellier, France; Horsham, United Kingdom)
Source:
Annual Congress 2004 - New and emerging pharmacological strategies in the treatment of asthma
Session:
New and emerging pharmacological strategies in the treatment of asthma
Session type:
Poster Discussion
Number:
1390
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Bousquet, G. Ayre, M. Blogg (Montpellier, France; Horsham, United Kingdom). Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification. Eur Respir J 2004; 24: Suppl. 48, 1390
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009
High risk COPD patients cost less if treated according to GOLD 2011 recommendations
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
COPD severity analysis according to current evaluation criteria – National survey
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Use of GINA classification of asthma severity in general practice
Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma
Year: 2003
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Sputum assessment in asthma management does not improve disease control when GINA step-up treatment is used in mild-to-moderate patients
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Usefulness of severity predictive scores in COPD exacerbations in hospitalized patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Improvement in symptoms, wheezing and pulmonary function tests of asthmatic patients due to application of GINA in their treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 842s
Year: 2006
Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Defining acute asthma severity – how do worldwide asthma guidelines compare?
Source: International Congress 2018 – The bad and the ugly in paediatric asthma: comorbidities and exacerbations
Year: 2018
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 7s
Year: 2005
Acute severe asthma: evidence-based management of asthma exacerbations
Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond
Year: 2008
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept